Please login to the form below

Not currently logged in
Email:
Password:

Patients prefer AZ asthma drug

Details of a recent study presented at the International Conference of the American Thoracic Society in Toronto showed that asthma patients prefer AstraZeneca's (AZ) Symbicort to GlaxoSmithKline's (GSK) Adviar.

Details of a recent study presented at the International Conference of the American Thoracic Society in Toronto showed that asthma patients prefer AstraZeneca's (AZ) Symbicort to GlaxoSmithKline's (GSK) Adviar.

Patients involved in the open-label study favoured Symbicort administered as an adjustable dose treatment option as opposed to Advair. The two drugs have a similar mode of action and are competing against each other in the large and lucrative asthma market.

"These data showed that patients treated with Symbicort combination therapy fixed dose were more satisfied with the timelines of their symptom relief than those patients treated with Advair combination," said Dr Richard O'Connor, lead investigator of the study.

Despite being available as an adjustable dose treatment in over 87 countries, Symbicort is not indicated for that use in the US but was launched as a long-term maintenance treatment last year.

GSK reported global sales of Adviar worth $6.4bn in 2007 where as AZ recorded sales worth $1.6bn during the same year.

21st May 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics